Bottom line
IPBNX vs VPMCX: the short answer
IPBNX (Allspring Real Return Fund) and VPMCX (Vanguard PRIMECAP Fund) are both mutual funds.
But VPMCX is far broader, holding 173 positions to 1 for IPBNX, so beyond the top names it adds exposure IPBNX doesn't have.
VPMCX is cheaper at 0.35% vs 0.45% — a difference of $10.00 a year per $10,000 invested.
Over five years, VPMCX returned +14.3% a year vs +4.4% for IPBNX.
Updated Nov 19, 2026
IPBNX vs VPMCX side by side
| IPBNX | VPMCX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Allspring | Vanguard |
| Category | Large Blend | Large Blend |
| Expense ratio | 0.45% | 0.35% |
| Annual cost per $10k | $45 | $35 |
| 10-yr cost on $10k (prospectus) | $803 | $443 |
| Max front load | 0% | 0% |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +11.2% | +29.9% |
| 5-yr return (annualized) | +4.4% | +14.3% |
| 10-yr return (annualized) | +4.7% | +15.2% |
| Best quarter | — | +17.3% |
| Worst quarter | — | −20.2% |
| Net assets (fund) | $219.8M | $96.1B |
| Number of holdings | 1 | 173 |
| Portfolio turnover | 59% | 11% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
IPBNX and VPMCX share none of their top holdings.
IPBNX top 10
- Allspring Real Return Portfolio — 99.71%
VPMCX top 10
- Micron Technology Inc — 13.50%
- Intel Corp — 6.80%
- Eli Lilly & Co — 6.76%
- KLA Corp — 3.85%
- Alphabet Inc — 3.52%
- AstraZeneca PLC — 2.35%
- NVIDIA Corp — 2.33%
- Amazon.com Inc — 2.05%
- Tesla Inc — 1.89%
- Biogen Inc — 1.88%
FAQ
What is the difference between IPBNX and VPMCX?
IPBNX (Allspring Real Return Fund) and VPMCX (Vanguard PRIMECAP Fund) are both mutual funds. But VPMCX is far broader, holding 173 positions to 1 for IPBNX, so beyond the top names it adds exposure IPBNX doesn't have.
Which is cheaper, IPBNX or VPMCX?
VPMCX has the lower expense ratio (0.35%).
Should I own both IPBNX and VPMCX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.